RxDoctor Payments Data

Bobbi Bullock

Family · Nampa, IDNPI 1669620506

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $419,426 of the $609,350 with a category attached, or 68.8%. AbbVie accounts for 99.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $209,673 and has fallen 77.2% since, to $47,834 in 2025. Among family clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$609,350in general payments, 2019–2025

Across 1,010 payments — averaging $603.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$609K
  • Galderma Laboratories, L.p.$405
  • Revance Therapeutics, Inc.$49

What the payments were for

  • Consulting fees$90,90115%
  • Speaking & faculty fees$419,42669%
  • Travel & lodging$73,69212%
  • Food & beverage$25,1744%
  • Education$1560%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)1,002$608,896
Galderma Laboratories, L.p.6$405
Revance Therapeutics, Inc.2$49

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$609,350 in reported general payments places this provider in the 95th percentile of 809 family providers in Idaho.

See all family providers in Idaho

Other family in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →